Phase 1 Ovarian Cancer Trial, Recruiting NCT06143527 Sponsor: The Foundation for Orthopaedics and Regenerative Medicine Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 1 Ovarian Cancer Trial, Recruiting

NCT06143527
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with polycystic ovary syndrome (PCOS), confirmed by an ultrasound scan

Who may not be able to join:

  • People who currently have an active infection
  • People who currently have an active cancer diagnosis
  • People who have serious failure of multiple organs at the same time
  • People who are currently pregnant
  • People whose pre-treatment blood or lab test results show significant abnormalities
  • People with a medical condition that the trial investigator believes could put them at risk
  • People who are currently misusing drugs
  • People who have previously had an organ transplant
  • People who have a known allergy or sensitivity to sulfur
  • People who are unable to give proper informed consent (that is, those who are unable to fully understand and agree to participation in the trial)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chadwick C Prodromos, MD, The Foundation for Orthopaedics and Regenerative Medicine

Phone: 8476996810

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Registry
ClinicalTrials.gov
Start date
16 November 2023
Est. completion
16 November 2027

Where this trial is recruiting

Antigua and Barbuda 🇬🇷 Greece

Primary endpoints

Safety: Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov